Results 51 to 60 of about 9,925 (218)

Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A

Disease Models & Mechanisms, 2018
Growing evidence supports the implication of DYRK1A in the development of cognitive deficits seen in Down syndrome (DS) and Alzheimer's disease (AD).
Thu Lan Nguyen, Arnaud Duchon, Antigoni Manousopoulou, Nadège Loaëc, Benoît Villiers, Guillaume Pani, Meltem Karatas, Anna E. Mechling, Laura-Adela Harsan, Emmanuelle Limanton, Jean-Pierre Bazureau, François Carreaux, Spiros D. Garbis, Laurent Meijer, Yann Herault   +14 more
doaj   +1 more source

Chemical screening identifies the β-Carboline alkaloid harmine to be synergistically lethal with doxorubicin. [PDF]

, 2017
Despite being an invaluable chemotherapeutic agent for several types of cancer, the clinical utility of doxorubicin is hampered by its age-related and dose-dependent cardiotoxicity.
Ashour, M.E., Atteya, R., El-Khamisy, S.F., Farag, M.A., Ibrahim, E.E.   +4 more
core   +1 more source

Sex-specific developmental alterations in DYRK1A expression in the brain of a Down syndrome mouse model

Neurobiology of Disease
Aberrant neurodevelopment in Down syndrome (DS)—caused by triplication of human chromosome 21—is commonly attributed to gene dosage imbalance, linking overexpression of trisomic genes with disrupted developmental processes, with DYRK1A particularly ...
Laura E. Hawley, Megan Stringer, Abigail J. Deal, Andrew Folz, Charles R. Goodlett, Randall J. Roper   +5 more
doaj   +1 more source

Increased plasma DYRK1A with aging may protect against neurodegenerative diseases

Translational Psychiatry, 2023
Early markers are needed for more effective prevention of Alzheimer’s disease. We previously showed that individuals with Alzheimer’s disease have decreased plasma DYRK1A levels compared to controls.
Jean M. Delabar, Julien Lagarde, Marta Fructuoso, Ammara Mohammad, Michel Bottlaender, Eric Doran, Ira Lott, Isabelle Rivals, Frederic A. Schmitt, Elizabeth Head, Marie Sarazin, Marie-Claude Potier   +11 more
doaj   +1 more source

A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome [PDF]

, 2015
Down syndrome, caused by an extra copy of chromosome 21, is associated with a greatly increased risk of early onset Alzheimer disease. It is thought that this risk is conferred by the presence of three copies of the gene encoding amyloid precursor ...
A Coppus, A Goate, A Hirayama, A Karmiloff-Smith, A Letourneau, A Llado, A Ma'ayan, A Murray, A Patel, A Rovelet-Lecrux, A Rovelet-Lecrux, A Salehi, A Serrano-Pozo, A Strydom, AC Phillips, AH Ropper, AJ Dalton, AJ Holland, AM Cataldo, AMW Coppus, AMW Coppus, André Strydom, Annette Karmiloff-Smith, AW Bero, B Schmidt-Sidor, BL Burgess, BL Handen, BP Wang, BT Hyman, BV Hooli, BV Hooli, C Balducci, C Canzonetta, C Chen, C Mori, C Oliver, CA Lemere, CC Draheim, CF Lippa, CJ Holler, CY Chang, D Adams, D Allsop, D Friedman, D Jennings, D McNaughton, D Powell, D Wallon, DA Devenny, DA Devenny, Dean Nizetic, DM Wilcock, DMA Mann, DMA Mann, DMA Mann, DMA Mann, DMA Mann, DMA Mann, DS Yang, E Head, EA Shukkur, EL Jones, Elizabeth M. C. Fisher, EW Wolvetang, F Fernandez, F Liu, F Struwe, F Yamaguchi, FE Visser, FK Wiseman, Frances K. Wiseman, G Azkona, G d'Orsi, G de Graaf, G Drewes, G Esposito, GA Carlson, GG Glenner, GH Tansley, GM Murphy, H Braak, H Godridge, H Seo, H Thonberg, HM Evenhuis, HM Wisniewski, IH Park, IT Lott, IT Lott, J Busciglio, J Busciglio, J Chapman, J Fraser, J Jiang, J Landt, J Lejeune, J Motte, J Noebels, J Shi, J Tyrrell, J van de Louw, J Wegiel, J Wegiel, JA Hardy, JB deHaan, JB Leverenz, JC Cossec, JC Lambert, JC Moller, JE Donahue, JG Sheng, JH Lee, JH Wu, JH Wu, JHK Choi, JK Teller, JL Vazquez-Higuera, JO Korbel, John Hardy, JP Weick, JS Anderson, K Kasuga, K Murakami, K Sleegers, KA Gyure, KA Vossel, KE Wisniewski, KE Wisniewski, KS Naito, KT Chang, KY Mok, L Cabrejo, L Crayton, L Mucke, L Torroja, L Zhu, LB Li, LBJ McIntire, LD Nelson, LD Nelson, LJ Whalley, M Adorno, M Bothwell, M Goedert, M McCarron, M Nicolas, M Picard, M Vilardell, MC Irizarry, MC Masters, MC Phillips, MC Royston, MJ Ball, MJ Stampfer, ML Margallo-Lana, MO McCarron, MP Cosgrave, MS Cheon, N Schupf, N Schupf, P Zis, PC Burger, PJW Naude, PM Moran, PV Belichenko, QS Xue, R De Simone, R Egensperger, R Kimura, RA Armstrong, S Barbosa, S Deb, S Govoni, S Griffiths-Jones, S Horvath, S Moore, S Swaminathan, S Swaminathan, S Takashima, S Ylaherttuala, SA Cooper, SA Purro, SJ Krinsky-McHale, SJ Krinsky-McHale, SL Ball, SL Ball, SL Hartley, SM Mills, SR Ryoo, SV Matveev, T Iwatsubo, T Lu, T Mendel, T Mori, Tamara Al-Janabi, V Brault, V Cvetkovska, V Dorval, VH Perry, Victor L. J. Tybulewicz, VP Prasher, VP Prasher, VP Prasher, WB Zigman, WB Zigman, WB Zigman, WB Zigman, WK Dowjat, WRG Gibb, WS Kim, WST Griffin, X Wang, XL Sun, Y Hibaoui, Y Jiang, Y Stern, YC Shi, YH Li, YL Woods, YS Davidson   +219 more
core   +1 more source

DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity

eLife
DYRK1A, a ubiquitously expressed kinase, is linked to the dominant intellectual developmental disorder, microcephaly, and Down syndrome in humans. It regulates numerous cellular processes such as cell cycle, vesicle trafficking, and microtubule assembly.
Pinhua Wang, Sunayana Sarkar, Menghuan Zhang, Tingting Xiao, Fenhua Kong, Zhe Zhang, Deepa Balasubramanian, Nandan Jayaram, Sayantan Datta, Ruyu He, Ping Wu, Peng Chao, Ying Zhang, Michael Washburn, Laurence A Florens, Sonal Nagarkar-Jaiswal, Manish Jaiswal, Man Mohan   +17 more
doaj   +1 more source

A New Vista of Opportunity in Diabetes Management: Natural Product‐Based β‐cell Preservation

Food Chemistry International, EarlyView.
Preserving functional β‐cells via natural products offers promising strategy for diabetes treatment. ABSTRACT A defining characteristic of diabetes is β‐cell failure, in which β‐cells cannot modulate insulin secretion to compensate for escalating insulin resistance, pushing forward disease development.
Yi‐San Lee, Tien‐Fen Kuo, Chun‐Yen Yang, Greta Yang, Wen‐Chin Yang   +4 more
wiley   +1 more source

DYRK1A antagonists rescue degeneration and behavioural deficits of in vivo models based on amyloid-β, Tau and DYRK1A neurotoxicity

Scientific Reports, 2022
AbstractAlzheimer’s disease (AD) involves pathological processing ofamyloid precursor protein(APP) into amyloid-β andmicrotubule associated protein Tau(MAPT)into hyperphosphorylated Tau tangles leading to neurodegeneration. Only 5% of AD cases are familial making it difficult to predict who will develop the disease thereby hindering our ability to ...
Bangfu Zhu, Tom Parsons, Christopher Foley, Yeng Shaw, Travis Dunckley, Christopher Hulme, James J. L. Hodge   +6 more
openaire   +3 more sources

Alterations in the phenotype of neocortical pyramidal cells in the Dyrk1A+/− mouse

Neurobiology of Disease, 2005
The gene encoding the dual-specificity tyrosine-regulated kinase DYRK1A maps to the chromosomal segment HSA21q22.2, which lies within the Down syndrome critical region.
R. Benavides-Piccione, M. Dierssen, I. Ballesteros-Yáñez, M. Martínez de Lagrán, M.L. Arbonés, V. Fotaki, J. DeFelipe, G.N. Elston   +7 more
doaj   +1 more source

Multi‐Targeting Ligands as Prospective Therapeutics for Alzheimer's Disease, a Prevalent Neurodegenerative Disorder: Mechanistic Insights, Emerging Targets and Drug Discovery Campaigns

Medicinal Research Reviews, EarlyView.
ABSTRACT Alzheimer's disease (AD) is a debilitating neurodegenerative condition characterized by progressive cognitive impairment, memory deterioration, and neuronal dysfunction. Its complex pathophysiology involves multiple interlinked processes, including amyloid‐β (Aβ) aggregation, tau hyperphosphorylation, oxidative stress, neuroinflammation ...
Amandeep Thakur, Mandeep Rana, Sakshi Vanjani, Kei‐Chi Liou, Rajeev Taliyan, Kunal Nepali, Chih‐Hao Yang   +6 more
wiley   +1 more source